Lupin Limited (NSE:LUPIN) — Market Cap & Net Worth
Market Cap & Net Worth: Lupin Limited (LUPIN)
Lupin Limited (NSE:LUPIN) has a market capitalization of $11.26 Billion (Rs1.04 Trillion) as of June 17, 2026. Listed on the NSE stock exchange, this India-based company holds position #2074 globally and #79 in its home market, demonstrating a 1.03% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lupin Limited's stock price Rs2277.80 by its total outstanding shares 456967946 (456.97 Million). Review how much debt does Lupin Limited carry to assess the company's total debt and financial obligations.
Lupin Limited Market Cap History: 2015 to 2026
Lupin Limited's market capitalization history from 2015 to 2026. Data shows growth from $8.63 Billion to $11.26 Billion (1.37% CAGR).
Index Memberships
Lupin Limited is a constituent of 13 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY PHARMA
CNXPHARMA
|
$91.62 Billion | 12.29% | #3 of 20 |
|
NIFTY GROWTH SECTORS 15
NI15
|
$259.44 Billion | 4.34% | #8 of 15 |
|
NIFTY MIDCAP 100
NIFMDCP100
|
$529.74 Billion | 2.12% | #9 of 100 |
|
NIFTY100 EQUAL WEIGHT
NIFTY100EW
|
$1.76 Trillion | 0.64% | #52 of 99 |
|
NIFTY 200
NIFTY200
|
$2.55 Trillion | 0.44% | #73 of 200 |
|
NIFTY 500
NIFTY500
|
$3.11 Trillion | 0.36% | #74 of 500 |
|
NIFTY HEALTHCARE
NIFTYHEALTHCARE
|
$110.04 Billion | 10.23% | #5 of 20 |
|
Nifty Low Volatility 50
NIFTYLVI
|
$958.95 Billion | 1.17% | #25 of 48 |
|
NIFTY MIDCAP 150
NIFTYMIDCAP150
|
$710.08 Billion | 1.59% | #10 of 150 |
|
NIFTY MIDCAP SELECT
NIFTYMIDSELECT
|
$172.51 Billion | 6.53% | #5 of 25 |
|
NIFTY MIDSMALLCAP 400
NIFTYMIDSML400
|
$1.14 Trillion | 0.99% | #14 of 400 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$3.20 Trillion | 0.35% | #74 of 750 |
|
NIFTY MIDCAP 50
NIMDCP50
|
$303.06 Billion | 3.71% | #7 of 50 |
Weight: Lupin Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Lupin Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lupin Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.05x
Lupin Limited's market cap is 0.05 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.32x
Lupin Limited's market cap is 0.32 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $7.02 Billion | $141.32 Billion | $22.61 Billion | 0.05x | 0.31x |
| 2017 | $4.20 Billion | $173.67 Billion | $25.57 Billion | 0.02x | 0.16x |
| 2018 | $4.04 Billion | $157.77 Billion | $2.51 Billion | 0.03x | 1.61x |
| 2019 | $3.67 Billion | $146.65 Billion | $6.07 Billion | 0.03x | 0.61x |
| 2020 | $4.73 Billion | $153.75 Billion | -$2.69 Billion | 0.03x | N/A |
| 2021 | $4.63 Billion | $151.63 Billion | $12.17 Billion | 0.03x | 0.38x |
| 2022 | $3.59 Billion | $164.05 Billion | -$15.28 Billion | 0.02x | N/A |
| 2023 | $6.51 Billion | $166.42 Billion | $4.30 Billion | 0.04x | 1.51x |
| 2024 | $11.64 Billion | $200.11 Billion | $19.14 Billion | 0.06x | 0.61x |
| 2025 | $10.43 Billion | $227.08 Billion | $32.82 Billion | 0.05x | 0.32x |
Competitor Companies of LUPIN by Market Capitalization
Companies near Lupin Limited in the global market cap rankings as of June 17, 2026.
Key companies related to Lupin Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #513 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #561 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #624 globally with a market cap of $44.20 Billion USD ( CN¥302.05 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #513 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #561 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.22 |
| #624 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.20 Billion | CN¥47.35 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
Lupin Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Lupin Limited's market cap moved from $8.63 Billion to $ 11.26 Billion, with a yearly change of 1.37%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs11.26 Billion | +7.98% |
| 2025 | Rs10.43 Billion | -10.45% |
| 2024 | Rs11.64 Billion | +78.84% |
| 2023 | Rs6.51 Billion | +81.09% |
| 2022 | Rs3.59 Billion | -22.35% |
| 2021 | Rs4.63 Billion | -2.13% |
| 2020 | Rs4.73 Billion | +28.79% |
| 2019 | Rs3.67 Billion | -8.99% |
| 2018 | Rs4.04 Billion | -4.02% |
| 2017 | Rs4.20 Billion | -40.08% |
| 2016 | Rs7.02 Billion | -18.71% |
| 2015 | Rs8.63 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Lupin Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $11.26 Billion USD |
| MoneyControl | $11.26 Billion USD |
| MarketWatch | $11.26 Billion USD |
| marketcap.company | $11.26 Billion USD |
| Reuters | $11.26 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lupin Limited
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutica… Read more